Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
Raw ttl | Download
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Evidence ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "267236"] ; #
fhir:meta [
fhir:versionId [ fhir:v "9" ] ;
fhir:lastUpdated [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime ] ;
( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ;
fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] )
] ; #
fhir:language [ fhir:v "en"] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 267236</b></p><a name=\"267236\"> </a><a name=\"hc267236\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/267236\">https://fevir.net/resources/Evidence/267236</a></p><p><b>identifier</b>: FEvIR Object Identifier/267236, FEvIR Linking Identifier/NCT03421379-secondaryOutcomeMeasure-1--OG000</p><p><b>name</b>: NCT03421379_secondaryOutcomeMeasure_1_OG000</p><p><b>title</b>: PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379</p><p><b>citeAs</b>: </p><div><p>PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json.</p>\n</div><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>note</b>: , </p><blockquote><div><p>Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PD data.</p>\n</div></blockquote><blockquote><div><p>Outcome Measure Denominator Units: Participants</p>\n</div></blockquote><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-267228.html\">PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration - (NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000574}\">median</span></p><p><b>quantity</b>: 1 hour</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Full Range</span></td><td>0.5-4.02 hour</td></tr></table></blockquote></div>"^^rdf:XMLLiteral ]
] ; #
fhir:url [
fhir:v "https://fevir.net/resources/Evidence/267236"^^xsd:anyURI ;
fhir:l <https://fevir.net/resources/Evidence/267236>
] ; #
fhir:identifier ( [
fhir:type [
( fhir:coding [
fhir:system [
fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ;
fhir:l <http://terminology.hl7.org/CodeSystem/v2-0203> ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ] ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ;
fhir:system [
fhir:v "https://fevir.net/FOI"^^xsd:anyURI ;
fhir:l <https://fevir.net/FOI> ] ;
fhir:value [ fhir:v "267236" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] [
fhir:type [
fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ;
fhir:system [
fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
fhir:l <https://fevir.net/FLI> ] ;
fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-1--OG000" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] ) ; #
fhir:name [ fhir:v "NCT03421379_secondaryOutcomeMeasure_1_OG000"] ; #
fhir:title [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"] ; #
fhir:citeAs [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json."] ; #
fhir:status [ fhir:v "active"] ; #
fhir:author ( [
fhir:name [ fhir:v "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter" ]
] ) ; #
fhir:publisher [ fhir:v "Computable Publishing LLC"] ; #
fhir:contact ( [
( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ] ] )
] ) ; #
fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; #
fhir:description [ fhir:v "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."] ; #
fhir:variableDefinition ( [
fhir:description [ fhir:v "Glucagon Nasal Powder" ] ;
( fhir:note [
fhir:text [ fhir:v "Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PD data." ] ] [
fhir:text [ fhir:v "Outcome Measure Denominator Units: Participants" ] ] ) ;
fhir:variableRole [ fhir:v "population" ] ;
fhir:observed [
fhir:identifier [
fhir:type [
fhir:text [ fhir:v "ClinicalTrials.gov Outcome Measurement Group Id" ] ] ;
fhir:value [ fhir:v "OG000" ] ] ;
fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ]
] [
fhir:variableRole [ fhir:v "outcome" ] ;
fhir:observed [
fhir:l fhir:EvidenceVariable/267228 ;
fhir:reference [ fhir:v "EvidenceVariable/267228" ] ;
fhir:type [
fhir:v "EvidenceVariable"^^xsd:anyURI ;
fhir:l fhir:EvidenceVariable ] ;
fhir:identifier [
fhir:type [
fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ;
fhir:system [
fhir:v "https://fevir.net/FLI"^^xsd:anyURI ;
fhir:l <https://fevir.net/FLI> ] ;
fhir:value [ fhir:v "NCT03421379-secondaryOutcome-1" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ;
fhir:display [ fhir:v "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration - (NCT03421379)" ] ]
] ) ; #
fhir:statistic ( [
fhir:statisticType [
( fhir:coding [
fhir:system [
fhir:v "https://fevir.net/sevco"^^xsd:anyURI ;
fhir:l <https://fevir.net/sevco> ] ;
fhir:code [ fhir:v "STATO:0000574" ] ;
fhir:display [ fhir:v "median" ] ] ) ] ;
fhir:quantity [
fhir:value [ fhir:v "1"^^xsd:decimal ] ;
fhir:unit [ fhir:v "hour" ] ] ;
fhir:sampleSize [
fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ;
( fhir:attributeEstimate [
fhir:type [
fhir:text [ fhir:v "Full Range" ] ] ;
fhir:range [
fhir:low [
fhir:value [ fhir:v 0.5 ] ;
fhir:unit [ fhir:v "hour" ] ] ;
fhir:high [
fhir:value [ fhir:v 4.02 ] ;
fhir:unit [ fhir:v "hour" ] ] ] ] )
] ) . #
|
Propose a change